Charting a Pathway to Personalized Medicine
Regulatory Challenges Loom for Companion Diagnostics
By Marie Powers
Thursday, June 7, 2012
The biotech industry's interest in companion diagnostics has grown in concert with the recognition that those tests can offer an approval pathway for narrowly effective and costly biologics targeting specific biomarkers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.